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A variety of novel strategies for treating solid tumors by al. 1995; Xu et al. 1997). Enthusiasm has continued
after a phase I clinical trial where injection of lung tu-gene therapy have been developed in recent years. A
signiﬁcant limitation in many of these methods is the mors with a p53 retrovirus was nontoxic and suppressed
tumor growth in six of nine patients (Roth et al. 1996).ability to transfer therapeutic genes uniformly into all
tumor cells in situ. To increase cell killing within tumors However, the ﬁeld of tumor-suppressor gene therapy
is limited by the paucity of identiﬁed target genes knownand render metastatic disease managable, new strategies
will be needed to deliver therapeutic genes systemically to induce or maintain the malignant phenotype. Further-
more, in preclinical in situ studies, eradication of treatedor to induce systemic antitumor responses following lo-
cal therapy. Potential shortcomings of these approaches tumors is a rarity, given the difﬁculty in transduction of
sufﬁcient numbers of cells within a cancer to facilitatemay be addressed through the positive phenomenon of
a ‘‘bystander effect’’ to broaden the destructive effects a cure. A bystander effect, whereby more cells die than
are transduced, has been proposed, but neither its sig-of a given therapy. Bystander effects may act locally,
via cell-cell contact, or systemically, through immune- niﬁcance nor a speciﬁc mechanism(s) has yet been identi-
ﬁed (Fujiwara et al. 1994; Lesoon-Wood et al. 1995;mediated responses. This short review will explore the
ability of the three most widely studied approaches to Xu et al. 1997). Mutant or absent p53 status has been
associated with resistance to radiation therapy and tocancer gene therapy and will critically evaluate each
one’s ability to affect local growth and metastases and apoptosis-inducing chemotherapy (Lowe et al. 1994).
Indeed, the combination of p53 gene transduction withto provoke a deﬁned bystander effect.
radiation or chemotherapy has resulted in local tumor
control superior to either therapy alone (Gjerset et al.Tumor-Suppressor Gene Therapy
1995; Ngyuyen et al. 1996) and is currently under inves-
Cancer gene therapy in its purest form is the replace-
tigation in clinical trial.
ment, with a correct copy, of a gene whose mutation
Direct suppression of metastatic growth through p53
initiates or signiﬁcantly alters the malignant phenotype.
gene therapy has been attempted through systemic deliv-
Cell death may not be the sole goal of such treatment:
ery of a liposome complex in a breast cancer model
changes in growth, behavior, invasiveness, or metastatic
(Lesoon-Wood et al. 1995) or via hepatic-artery infusion
ability represent other important goals in cancer con-
for colonic liver metastases (Bookstein et al. 1996), al-
tainment. Since p53 is the most commonly mutated gene
though both approaches lack tumor targeting. A novel
in human cancer and inﬂuences transcription, cell-cycle
strategy to address the treatment of p53mutant metasta-
arrest, DNA repair, and apoptosis (Harris 1996) as well
ses has been the development of an adenovirus that repli-
as angiogenesis (Dameron et al. 1994), it has received
cates only within p53 mutant cells, killing through cell
the most interest as a target for cancer gene therapy.
lysis (Bischoff et al. 1996). Although not truly gene ther-
Transduction of cancer cells with p53 can signiﬁcantly
apy, systemic inoculation of this vector has resulted in
inhibit growth and angiogenesis or can induce apoptosis
signiﬁcant growth suppression of a primary tumor
in p53 mutant cells in several tumor models, including
(Heise et al. 1997) and deserves further investigation.
lung and breast (Fujiwara et al. 1994; Lesoon-Wood et
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The CD gene converts 5-FC to the chemotherapeutic Use of HSV-tk plus GCV for the treatment of meta-
static disease presents several problems. Treatment ofagent, 5-ﬂuorouracil (5-FU) (Huber et al. 1993) and has
been studied centrally as a treatment for hepatic metasta- tumors with HSV-tk suppresses growth of tumors de-
rived from challenge injections of the parental cell line,ses of gastrointestinal tumors, for which 5-FU is com-
monly used. A signiﬁcant bystander effect is active indicating the induction of systemic antitumor activity
in some models (Barba et al. 1994; Vile et al. 1994).through production of locally high levels of freely diffus-
ible 5-FU (Trinh et al. 1995). Systemic therapy with 5-FC Some evidence exists that this suppression is mediated
by immune cells (Vile et al. 1994; Yamamoto et al.results in growth suppression of CD-transduced tumors,
whereas little suppression is achieved in the same tumors 1997), but the signiﬁcance and generality of these obser-
vations are largely unknown. Furthermore, systemic de-with high doses of systemic 5-FU (Huber et al. 1993). No
systemic growth suppression was seen in nontransduced livery of HSV-tk to target metastatic lesions through
intravenous (Vile et al. 1994) or peritoneal (Tong et al.tumors growing in the same animals, indicating the lack
of serum 5-FU levels sufﬁcient for antitumor activity. 1996; Yee et al. 1996) routes may lead to signiﬁcant
liver injury (Yee et al. 1996; Brand et al. 1997; Qian etHowever, other investigators have noted that successful
treatment of CD-transduced tumors with 5-FC can result al. 1997); tissue-speciﬁc vectors may be required for safe
systemic delivery of this gene.in activity against challenge tumors (Mullen et al. 1994).
Depletion of CD8/ T-cells or granulocytes abrogates the
effects of CD plus 5-FC (Consalvo et al. 1995) in poorly Immunomodulatory Gene Therapy
immunogenic models, indicating possible immunological
activity in this system. Immunomodulatory gene therapy has been explored
as a method to provoke cellular immune responses toStrategies for treating liver metastases have focused on
regional delivery of the CD gene into areas surrounding metastatic lesions. A tumor vaccine, a suspension of irra-
diated tumor cells that are transduced with a cytokinemetastases (Ohwada et al. 1996. Further reﬁnements for
systemic gene delivery are being explored through the gene, is injected into the skin of a patient to stimulate
a systemic immune response against tumor-speciﬁc anti-use of tissue-speciﬁc promoters, such as carcinoembry-
onic antigen (CEA) or a-fetoprotein genes, for tumor gens. In numerous preclinical cancer models, vaccina-
tion with tumor cells expressing IL-2, GM-CSF, or IFN-targeting after hepatic-artery infusion of the CD vector
(Richards et al. 1995; Kanai et al. 1997). However, out- g can generate cellular immunological activity against
challenge tumors (Fearon et al. 1990; Gansbacher et al.standing issues with this approach include the develop-
ment of resistance to 5-FU and the degree of killing in 1990a, 1990b) and, in many cases, can cure or signiﬁ-
cantly control the growth of preestablished local or met-tumors resistant to 5-FU.
HSV-tk phosphorylates GCV, converting it to a nucle- astatic tumors (Dranoff et al. 1993; Porgador et al.
1993a, 1993b; Vieweg et al. 1994). However, severaloside analogue that inhibits DNA synthesis (Moolten
1986). This metabolic change causes a signiﬁcant by- problems need to be addressed if this approach is to be
practical. First, few candidate tumor-speciﬁc antigens tostander effect through several mechanisms: gap junc-
tions transport nondiffusible phosphorylated GCV to act as recognition targets have been identiﬁed. Second,
in some studies, antitumor activity is only active againstnontransduced cells; nontransduced cells endocytose de-
bris containing phosphorylated GCV from dying cells; relatively low tumor burdens, predicting a potential dif-
ﬁculty in treating patients with large volume, establishedand an induced immune response leads to tumor killing
(Vile et al. 1994; Elshami et al. 1996b; Hamel et al. metastatic disease. Furthermore, although vaccination
therapy of subcutaneous tumors generates superior re-1996; Mesnil et al. 1996). This therapy has been ex-
plored for a variety of cancers, including localized brain sults, vaccination therapy of orthotopically placed tu-
mors has not been as successful (Vieweg et al. 1994),tumors (Culver et al. 1992; Barba et al. 1994; Chen et
al. 1994b) and mesotheliomas (Elshami et al. 1996a), indicating potential problems in inducing potent antitu-
mor immunological activities throughout the body afterliver metastases (Caruso et al. 1993), and peritoneal-
based metastases (Tong et al. 1996; Yee et al. 1996), subcutaneous vaccination. Last, this strategy involves
the costly and time-consuming process of tumor harvest-leading to ú35 clinical trials using this approach for
human cancers worldwide. Although the growth-sup- ing, ex vivo culturing, transfection and selection, and
outgrowth of sufﬁcient cells for injection.pressive activities of HSV-tk plus GCV are signiﬁcant,
cure rates are low, undoubtedly because of in situ trans- A combination of cytokine and costimulatory mole-
cule vaccination shows promise as a way to increaseduction inadequacies and the variability of the bystander
effect. As with p53 gene therapy, both the CD and HSV- the efﬁciency of tumor vaccines (Salvadori et al. 1995;
Gaken et al. 1997). The most widely investigated co-tk systems sensitize cancer cells to radiation, suggesting
possible combination therapies to control advanced tu- stimulatory molecule, B7, interacts with the CD28 re-
ceptor on T-cells to enhance T-cell activation (Linsleymors (Kim et al. 1995; Khil et al. 1996).
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and Ledbetter 1993). Transfection of B7 alone into tu- techniques to induce transgene expression or antitumor
responses at a systemic level. While deﬁned bystandermor cells inhibits tumor growth, through immunological
activity (Chen et al. 1992; Townsend and Allison 1993). effects enhance tumor killing, further evolutions in vec-
tor development, a thorough understanding of tumorThis activity may be present only in cell lines that are
inherently immunogenic (Chen et al. 1994a) and may and cellular immunology, and the expansion of thera-
pies that restrict angiogenesis will be necessary for ad-not necessarily lead to systemic immunity (Wu et al.
1995; Chong et al. 1996), but covaccination of B7 with vancement of the course of cancer gene therapy.
IL-2 (Salvadori et al. 1995; Gaken et al. 1997) markedly
enhances this activity and may deﬁne future approaches
to the improvement of vaccination strategies. References
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